COSELA
Total Payments
$17.5M
Transactions
14,059
Doctors
4,804
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $45,855 | 2,224 | 1,561 |
| 2023 | $5.7M | 4,693 | 2,163 |
| 2022 | $11.5M | 5,766 | 2,301 |
| 2021 | $354,126 | 1,376 | 866 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16.0M | 3,356 | 91.2% |
| Honoraria | $968,664 | 449 | 5.5% |
| Food and Beverage | $250,221 | 9,885 | 1.4% |
| Consulting Fee | $87,735 | 29 | 0.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $86,810 | 24 | 0.5% |
| Travel and Lodging | $82,542 | 286 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $37,150 | 17 | 0.2% |
| Education | $21,920 | 8 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,750 | 5 | 0.0% |
Payments by Type
Research
$16.0M
3,356 transactions
General
$1.5M
10,703 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) | G1 Therapeutics, Inc. | $10.8M | 3 |
| G1T28-207 | G1 Therapeutics, Inc. | $2.7M | 1 |
| G1T28-213 | G1 Therapeutics, Inc. | $869,055 | 0 |
| A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3) | G1 Therapeutics, Inc. | $613,331 | 2 |
| A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) | G1 Therapeutics, Inc. | $552,297 | 3 |
| G1T28-212 | G1 Therapeutics, Inc. | $287,516 | 0 |
| G1T28-113 | G1 Therapeutics, Inc. | $62,487 | 0 |
| G1T38-03 | G1 Therapeutics, Inc. | $26,761 | 0 |
| G1T48-01 | G1 Therapeutics, Inc. | $3,118 | 0 |
| A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4) | G1 Therapeutics, Inc. | $2,778 | 0 |
Top Doctors Receiving Payments for COSELA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Medical Oncology | New York, NY | $3,480 | 1 |
| , M.D | Medical Oncology | Houston, TX | $3,480 | 1 |
| , MD, PHD | Otolaryngology | Boston, MA | $3,480 | 1 |
| , MD, MS | Internal Medicine | Tampa, FL | $3,433 | 5 |
| , M.D | Urology | Philadelphia, PA | $3,250 | 1 |
| , MD | Hematology & Oncology | Houston, TX | $3,225 | 5 |
| , M.D | Internal Medicine | Bronx, NY | $3,032 | 3 |
| Peter Odonnell | Internal Medicine | Chicago, IL | $3,025 | 2 |
| , M.D | Hematology & Oncology | New York, NY | $3,019 | 4 |
| , M.D. PH.D | Medical Oncology | New York, NY | $3,007 | 2 |
| , M.D., PH.D | Hematology & Oncology | New York, NY | $3,007 | 2 |
| , MD | Internal Medicine | Burlington, MA | $3,007 | 2 |
| , M.D., PHD | Hematology & Oncology | Newport News, VA | $3,000 | 2 |
| , MBBS | Hematology & Oncology | Medford, OR | $3,000 | 2 |
| , MD | Hematology & Oncology | Hamilton, OH | $3,000 | 2 |
| , MD | Hematology & Oncology | Topeka, KS | $3,000 | 2 |
| , M.D | Medical Oncology | El Paso, TX | $3,000 | 2 |
| , M.D | Medical Oncology | Baltimore, MD | $2,987 | 4 |
| , MD | Hematology & Oncology | Gainesville, FL | $2,961 | 4 |
| , MD | Internal Medicine | Santa Monica, CA | $2,937 | 2 |
| , MD | Medical Oncology | Bolivar, MO | $2,816 | 2 |
| , M.D | Hematology & Oncology | Seattle, WA | $2,816 | 4 |
| , M.D | Medical Oncology | Boston, MA | $2,800 | 1 |
| , MD | Hematology & Oncology | Aurora, CO | $2,800 | 1 |
| , MD | Internal Medicine | Stanford, CA | $2,751 | 3 |
Ad
Manufacturing Companies
- G1 Therapeutics, Inc. $17.4M
- Pharmacosmos Therapeutics Inc. $45,656
- Boehringer Ingelheim Pharmaceuticals, Inc. $21,584
Product Information
- Type Drug
- Total Payments $17.5M
- Total Doctors 4,804
- Transactions 14,059
About COSELA
COSELA is a drug associated with $17.5M in payments to 4,804 healthcare providers, recorded across 14,059 transactions in the CMS Open Payments database. The primary manufacturer is G1 Therapeutics, Inc..
Payment data is available from 2021 to 2024. In 2024, $45,855 was paid across 2,224 transactions to 1,561 doctors.
The most common payment nature for COSELA is "Unspecified" ($16.0M, 91.2% of total).
COSELA is associated with 10 research studies, including "A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2)" ($10.8M).